[go: up one dir, main page]

AR034757A1 - Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos - Google Patents

Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos

Info

Publication number
AR034757A1
AR034757A1 ARP020102572A ARP020102572A AR034757A1 AR 034757 A1 AR034757 A1 AR 034757A1 AR P020102572 A ARP020102572 A AR P020102572A AR P020102572 A ARP020102572 A AR P020102572A AR 034757 A1 AR034757 A1 AR 034757A1
Authority
AR
Argentina
Prior art keywords
agent
pump
proton
pharmaceutical formulation
formulation including
Prior art date
Application number
ARP020102572A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR034757A1 publication Critical patent/AR034757A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tableta multiparticulada, que se desintegra en la boca que contiene: i) un agente para inhibir la bomba de protones, en particular del tipo benzimidazol, en la forma de microgránulos con capas de revestimiento entérico y que están sobre-revestidos con, al menos, un revestimiento de barrera como por ejemplo, una película protectora basada en un polímero metacrílico; ii) al menos un antiácido en la forma de gránulos por ejemplo, basado en CaCO3, y/o Mg(OH)2 y/o Al(OH)3; y iii) una mezcla de excipientes que comprenden al menos un agente desintegrante, un agente diluyente, un lubricante y, opcionalmente, un agente para la dilatación, un agente permeabilizante, endulzantes, saborizantes y colores. Procesos para la fabricación de la tableta y su utilización en el tratamiento de los trastornos gastrointestinales.
ARP020102572A 2001-07-16 2002-07-10 Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos AR034757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01401896 2001-07-16

Publications (1)

Publication Number Publication Date
AR034757A1 true AR034757A1 (es) 2004-03-17

Family

ID=8182807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102572A AR034757A1 (es) 2001-07-16 2002-07-10 Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos

Country Status (24)

Country Link
US (2) US20040219211A1 (es)
EP (1) EP1416922A1 (es)
JP (1) JP2004536855A (es)
KR (1) KR20040018463A (es)
CN (1) CN100469366C (es)
AR (1) AR034757A1 (es)
AU (1) AU2002316020B2 (es)
BG (1) BG108515A (es)
BR (1) BR0211117A (es)
CA (1) CA2453290A1 (es)
CO (1) CO5550417A2 (es)
HU (1) HUP0401941A3 (es)
IL (1) IL159584A0 (es)
IS (1) IS7111A (es)
MX (1) MXPA04000385A (es)
MY (1) MY136137A (es)
NO (1) NO20040178L (es)
NZ (1) NZ530511A (es)
PL (1) PL367686A1 (es)
RU (1) RU2301662C2 (es)
UA (1) UA75673C2 (es)
UY (1) UY27385A1 (es)
WO (1) WO2003007917A1 (es)
ZA (1) ZA200400285B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100408029C (zh) 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
JP3841804B2 (ja) * 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
EP1682087A1 (en) * 2003-11-07 2006-07-26 Takeda Pharmaceutical Company Limited Chewable tablet
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
EP1621187A1 (en) * 2004-07-26 2006-02-01 AstraZeneca AB Pharmaceutical multiparticulate tablet formulations and process for their preparation
US8057820B2 (en) 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102005024614A1 (de) * 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
JP2011509265A (ja) * 2008-01-10 2011-03-24 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 活性物質のパルス放出が強化された、コーティングされた医薬製剤もしくはニュートラシューティカル製剤
US20110070302A2 (en) * 2008-01-10 2011-03-24 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
RU2497503C9 (ru) * 2008-03-10 2014-09-20 Байер Конзюмер Кер АГ Приятная на вкус твердая композиция, включающая нейтрализатор кислотности и стимулятор слюноотделения
AU2009224254A1 (en) 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
EP2358374B1 (en) * 2008-11-17 2013-09-18 Takeda Nycomed AS Improved dissolution stability of calcium carbonate tablets
SG190717A1 (en) * 2010-12-03 2013-07-31 Takeda Pharmaceutical Orally disintegrating tablet
CN102085188B (zh) * 2011-01-14 2013-01-02 寿光富康制药有限公司 一种兰索拉唑肠溶微丸的制备方法
CN102078616A (zh) * 2011-01-28 2011-06-01 北京虹湾医药技术有限公司 埃索美拉唑碳酸氢钠组合物
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
CN103479593B (zh) * 2013-05-10 2014-10-08 青岛双鲸药业有限公司 一种奥美拉唑肠溶片的制备方法
JP6156037B2 (ja) * 2013-10-03 2017-07-05 ライオン株式会社 固形医薬製剤組成物
CN103784414B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3411018A1 (en) * 2016-02-03 2018-12-12 Novartis AG Galenic formulations of organic compounds
SG11201809555QA (en) * 2016-04-29 2018-11-29 Alan Thompson Veterinary composition
US10076494B2 (en) * 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108434117A (zh) * 2018-03-29 2018-08-24 成都通德药业有限公司 一种奥美拉唑肠溶胶囊的制备方法
RU2727506C1 (ru) * 2019-09-09 2020-07-22 Пивипи Лабс Пте. Лтд. Средство для лечения эректильной дисфункции
EP4070789A4 (en) * 2020-01-23 2024-01-24 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING A PROTON PUMP INHIBITOR AND AN ANTIACID
WO2022103233A1 (ko) * 2020-11-13 2022-05-19 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CN114617852B (zh) * 2020-12-10 2023-06-27 昆药集团股份有限公司 一种奥美拉唑肠溶制剂及其制备方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
AU2022381536A1 (en) 2021-11-05 2024-05-02 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516408B2 (ja) * 1988-08-18 1996-07-24 エスエス製薬株式会社 被覆顆粒を含む錠剤
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
JP3961596B2 (ja) * 1996-10-15 2007-08-22 富士化学工業株式会社 無機制酸剤含有速分散性造粒物、その製造方法及び用時懸濁内服制酸剤
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
SK180499A3 (en) * 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
WO2000078292A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
DE19954653B4 (de) * 1999-11-13 2006-01-19 Contitech Profile Gmbh Extruder zur Aufbereitung von Kautschukmischungen
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
DK1341528T3 (da) * 2000-12-07 2012-03-26 Nycomed Gmbh Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel

Also Published As

Publication number Publication date
RU2301662C2 (ru) 2007-06-27
RU2004101061A (ru) 2005-04-20
AU2002316020B2 (en) 2007-03-15
HUP0401941A2 (hu) 2005-01-28
MXPA04000385A (es) 2004-05-04
US20040219211A1 (en) 2004-11-04
PL367686A1 (en) 2005-03-07
HUP0401941A3 (en) 2008-04-28
BG108515A (en) 2005-02-28
CN100469366C (zh) 2009-03-18
NZ530511A (en) 2005-06-24
CN1555256A (zh) 2004-12-15
ZA200400285B (en) 2005-06-29
BR0211117A (pt) 2004-06-22
CA2453290A1 (en) 2003-01-30
JP2004536855A (ja) 2004-12-09
EP1416922A1 (en) 2004-05-12
IL159584A0 (en) 2004-06-01
WO2003007917A1 (en) 2003-01-30
MY136137A (en) 2008-08-29
CO5550417A2 (es) 2005-08-31
US20110135722A1 (en) 2011-06-09
IS7111A (is) 2004-01-15
KR20040018463A (ko) 2004-03-03
UY27385A1 (es) 2003-02-28
NO20040178L (no) 2004-03-16
UA75673C2 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
AR034757A1 (es) Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
AR043258A1 (es) Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
MX2009004874A (es) Formulaciones farmaceuticas estratificadas que comprenden una capa intermediaria que se disuelve rapidamente.
ES2168043A1 (es) Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
CO6721054A2 (es) Tableta oralmente desintegradora
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
ES2323268T3 (es) Formulaciones de liberacion prolongada que contienen lamotrigina.
MX9706785A (es) Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.
PE20051127A1 (es) Comprimido multicapa de telmisartan y ramipril
AR005280A1 (es) Forma de dosis efervescente unitaria multiple en tabletas, proceso para su fabricacion y uso de dicha forma para la fabricacion de medicamentos.
MX2013003286A (es) Tableta de multiples capas de desintegracion oral y su elaboracion.
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR087239A2 (es) Formulaciones farmaceuticas solidas que comprenden telmisartan
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
DE60313296D1 (de) Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten
AR072516A1 (es) Metodos, sistemas y dispositivos para la administracion de dioxido de cloro a un tejido
BRPI0414305A (pt) sistema de liberação de drogas por via oral
DE60235648D1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
EE04661B1 (et) Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
BR0307320A (pt) Sistema de liberação osmótico

Legal Events

Date Code Title Description
FB Suspension of granting procedure